What did @gearncoffee actually say?
The creator made a series of confident claims about GLP-1 receptor agonists, ranking them from worst to best and dismissing semaglutide as "obsolete." They said semaglutide "doesn't burn any fat" and "just makes you stop eating," while praising retatrutide and "trezetimide" (likely tirzepatide) for combining fat-burning with appetite suppression. They also name-dropped mazdutide as the next big thing, admitting they haven't tried or studied it yet, while still guaranteeing it "probably is better." The video ends with a joke about a future peptide that enlarges the penis. The overall message: GLP-1 therapy is a moving target, newer is always better, and you should be stacking peptides.
The candor about not having tried mazdutide is appreciated. The rest of the claims need serious scrutiny.
Does the science back this up?
Partially, but the framing is sloppy in ways that could genuinely mislead people. The claim that semaglutide "doesn't burn any fat" is flatly wrong. The idea that newer agents offer more mechanisms is mostly correct but overstated.
Semaglutide does produce fat loss. A 2021 trial by Wilding et al. in the New England Journal of Medicine showed patients on 2.4mg weekly semaglutide lost an average of 14.9% body weight over 68 weeks, with reductions in fat mass confirmed by DEXA imaging. The mechanism isn't purely appetite suppression either. GLP-1 receptors are expressed in adipose tissue, and there is evidence of direct lipolytic signaling, though appetite reduction is the dominant driver.
The creator is on firmer ground when suggesting tirzepatide outperforms semaglutide. Jastreboff et al. (2022, NEJM) showed tirzepatide at 15mg produced up to 22.5% mean body weight loss, exceeding semaglutide's trial results. Retatrutide, a triple agonist targeting GLP-1, GIP, and glucagon receptors, showed even larger weight loss numbers in Phase 2 data (Jastreboff et al., 2023, NEJM), with some participants losing over 24% body weight at 48 weeks. So the hierarchy the creator suggests has some real data behind it, even if the explanation for why is muddled.
What did they get wrong (or right)?
Wrong: "Semaglutide doesn't burn any fat." This is inaccurate. Weight lost on semaglutide is predominantly fat mass. The complaint about nausea and bloating is legitimate and well-documented, but that's a tolerability issue, not evidence the drug doesn't work.
Wrong: Stacking retatrutide and tirzepatide simultaneously. The creator says they are "on both" to get "shredding" from retatrutide and "suppression" from tirzepatide. There is no published safety or efficacy data for combining GLP-1 receptor agonists. Both drugs act on overlapping receptor pathways. Stacking them raises real concerns about additive gastrointestinal toxicity, hypoglycemia risk in susceptible individuals, and undefined pharmacokinetic interactions. FormBlends does not endorse this approach.
Mostly right: The argument that the therapeutic space is evolving rapidly is accurate. Mazdutide is a real drug in development, primarily studied in China for obesity and NAFLD, with Phase 3 data emerging. It is a GLP-1/glucagon dual agonist. Whether it "beats" retatrutide in head-to-head trials is unknown because those trials don't exist yet.
Right: Semaglutide was the pioneer. Approved first for type 2 diabetes in 2017, then obesity in 2021, it opened the clinical conversation that made everything else possible.
What should you actually know?
Newer GLP-1 agents do appear to produce greater weight loss in trials, but that doesn't make semaglutide "obsolete" for the millions of people who tolerate it well and are responding to it. Clinical decisions aren't made on TikTok rankings.
The pipeline is real. Retatrutide's triple-agonist mechanism is genuinely exciting. Mazdutide's dual GLP-1/glucagon profile offers a different metabolic angle, with some early data suggesting favorable effects on liver fat. But Phase 2 results rarely survive full contact with Phase 3 trials intact.
The stacking concern matters most here. Combining two GLP-1 pathway drugs without clinical supervision is not a strategy supported by any published evidence. It's an experiment the creator is running on themselves, and broadcasting it to 26,000 viewers as if it's a reasonable protocol is irresponsible. If you're interested in GLP-1 therapy, work with a licensed provider who can evaluate your individual health profile, not a peptide enthusiast who admits mid-video that he hasn't studied the drug he's recommending.